Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria

Advances in Therapy

Volumn 26, Issue 3, 2009, Pages 313-324

  Kohlmann Jr , Osvaldo ^a   Roca Cusachs, Alejandro ^b   Laurent, Stéphane ^c   Schmieder, Roland E ^d   Wenzel, René R ^e   Fogari, Roberto ^f  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e General Public Hospital Zell am See   (Austria)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Antihypertensive drugs; Delapril; Fixed dose combinations; Hydrochlorothiazide; Hypertension; Losartan; Manidipine; Microalbuminuria; Type 2 diabetes

Indexed keywords

CREATININE; DELAPRIL; DELAPRIL PLUS MANIDIPINE; GLUCOSE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; MANIDIPINE; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; BACKACHE; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HUMAN; HYPERTENSION; INFECTION; INFESTATION; INFLUENZA; INSOMNIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MICROALBUMINURIA; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URINARY TRACT DISEASE;

AGED; AGED, 80 AND OVER; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIHYDROPYRIDINES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; INDANS; LOSARTAN; MALE; MIDDLE AGED;

EID: 73449145094     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0015-8     Document Type: Article

References (35)

1. J. Stamler O. Vaccaro J.D. Neaton D. Wentworth 1993 Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 434 444 8432214 10.2337/diacare.16.2.434 1:STN:280:DyaK3s7mtFyrtQ%3D%3D
2. K.P. Klausen H.H. Parving H. Scharling J.S. Jensen 2007 The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality J Intern Med 262 470 478 17875184 10.1111/j.1365-2796.2007.01839.x 1:CAS:528: DC%2BD2sXht1ahtb7P (Pubitemid 47404367)
3. C.E. Mogensen 1984 Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes N Engl J Med 310 356 360 6690964 1:STN:280:DyaL2c%2FptlGjtA%3D%3D
4. R. Pontremoli G. Leoncini F. Viazzi 2005 Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension J Am Soc Nephrol 16suppl.1 S39 S41 10.1681/ASN.2004110955 (Pubitemid 41725081)
5. J.S. Jensen B. Feldt-Rasmussen S. Strandgaard M. Schroll K. Borch-Johnsen 2000 Arterial hypertension, microalbuminuria, and risk of ischemic heart disease Hypertension 35 898 903 10775558 1:STN:280:DC%2BD3c3ktVejsA%3D%3D
6. K. Borch-Johnsen B. Feldt-Rasmussen S. Strandgaard M. Schroll J.S. Jensen 1999 Urinary albumin excretion: an independent predictor of ischemic heart disease Arterioscler Thromb Vasc Biol 19 1992 1997 10446083 1:STN:280: DyaK1Mznslehug%3D%3D
7. R. Donnelly J.M. Yeung G. Manning 2003 Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes J Hypertens 21suppl.1 S7 S12
8. A.I. Adler R.J. Stevens S.E. Manley R.W. Bilous C.A. Cull R.R. Holman 2003 Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney Int 63 225 232 12472787 10.1046/j.1523-1755.2003.00712.x (Pubitemid 35463925)
9. L. Ryden E. Standl M. Bartnik 2007 The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary Eur Heart J. 28 88 136 17220161 10.1093/eurheartj/ehm124 1:CAS:528:DC%2BD2sXitlaiur8%3D (Pubitemid 47355991)
10. G. Mancia G. De Backer A. Dominiczak 2007 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 25 1105 1187 17563527 10.1097/HJH.0b013e3281fc975a 1:CAS:528:DC%2BD2sXmtlWnsr0%3D (Pubitemid 46924065)
11. American Diabetes Association. 2007 Standards of medical care in diabetes - 2007 Diabetes Care 30suppl.1 S4 S41 10.2337/dc07-S004 1:CAS:528: DC%2BD2sXhsF2ktro%3D (Pubitemid 46048398)
12. R.R. Wenzel 2005 Renal protection in hypertensive patients: selection of antihypertensive therapy Drugs 65suppl.2 29 39
13. P.L. McCormack G.M. Keating 2006 Delapril/manidipine Drugs 66 961 969 16740017 10.2165/00003495-200666070-00014 1:CAS:528:DC%2BD28Xnt1Cmtbo%3D (Pubitemid 43847379)
14. A. Roca-Cusachs R.E. Schmieder F. Triposkiadis 2008 Efficacy of manidipine/delapril versus losartan/HCTZ fixed combinations in patients with hypertension and diabetes J Hypertens 26 813 816 18327093 10.1097/HJH. 0b013e3282f3b5f0 1:CAS:528:DC%2BD1cXivFyjs7o%3D (Pubitemid 351354931)
15. A. Mugellini J. Dobovisek D. Planinc G. Cremonesi R. Fogari 2004 Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial Clin Ther 26 1419 1426 15531004 10.1016/j.clinthera.2004.09.018 1:CAS:528:DC%2BD2cXps1ansr4%3D (Pubitemid 39582712)
16. A. Mugellini P. Preti A. Zoppi 2004 Effect of delapril-manidipine combination vs irbesartanhydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus J Hum Hypertens 18 687 691 15071488 10.1038/sj.jhh.1001726 1:CAS:528:DC%2BD2cXnslelt7w%3D (Pubitemid 39369188)
17. J.T. Wright Jr. G. Bakris T. Greene 2002 Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 2421 2431 12435255 10.1001/jama.288.19.2421 1:CAS:528:DC%2BD38XoslOktr8%3D (Pubitemid 35340538)
18. R. Fogari L. Corradi A. Zoppi 2007 Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria Am J Hypertens 20 1092 1096 17903693 10.1016/j.amjhyper.2007.05.012 1:CAS:528:DC%2BD2sXhtFSnt77E (Pubitemid 47446175)
19. F.J. Martinez-Martin M. Saiz-Satjes 2008 Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study Expert Rev Cardiovasc Ther 6 1347 1355 19018688 10.1586/14779072.6.10.1347 1:CAS:528:DC%2BD1cXhsVSgsb%2FM
20. R.E. Schmieder J. Schrader W. Zidek 2007 Low grade albuminuria and cardiovascular risk Clin Res Cardiol 96 247 257 17453140 10.1007/s00392-007- 0510-3 1:CAS:528:DC%2BD2sXms1Sku7c%3D (Pubitemid 46740083)
21. G. Viberti N.M. Wheeldon 2002 MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure independent effect Circulation 106 672 678 12163426 10.1161/01.CIR.0000024416.33113.0A 1:CAS:528:DC%2BD38XmvFSmsL8%3D (Pubitemid 34851925)
22. C. Delles A.U. Klingbeil M.P. Schneider R. Handrock G. Weidinger R.E. Schmieder 2003 Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension Am J Hypertens 16 1030 1035 14643577 10.1016/j.amjhyper.2003.07.017 1:CAS:528:DC%2BD3sXpt1Wiurg%3D (Pubitemid 37500798)
23. P. Fioretto M. Bruseghin I. Berto P. Gallina E. Manzato M. Mussap 2006 Renal protection in diabetes: role of glycemic control J Am Soc Nephrol 17suppl.2 S86 S89 10.1681/ASN.2005121343
24. J. Bosch S. Yusuf 2006 DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes N Engl J Med. 355 1551 1562 16980380 10.1056/NEJMoa065061 (Pubitemid 44550032)
25. S.E. Kjeldsen S. Julius G. Mancia 2006 Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial J Hypertens 24 1405 1412 16794491 1:CAS:528:DC%2BD28XmtVOrsbk%3D 10.1097/01.hjh.0000234122.55895.5b (Pubitemid 43948341)
26. S. Yusuf H. Gerstein B. Hoogwerf 2001 Ramipril and the development of diabetes JAMA 286 1882 1885 11597291 10.1001/jama.286.15.1882 1:CAS:528:DC%2BD3MXns1yjurs%3D
27. R. Fogari A. Zoppi L. Corradi P. Lazzari A. Mugellini P. Lusardi 1998 Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients Br J Clin Pharmacol 46 467 471 9833600 10.1046/j.1365-2125.1998.00811.x 1:CAS:528:DyaK1cXnsFGmtr8%3D (Pubitemid 28484734)
28. D. Yavuz M. Koc A. Toprak 2003 Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients J Renin Angiotensin Aldosterone Syst 4 197 203 14608527 10.3317/jraas.2003.032 1:CAS:528:DC%2BD3sXpsFCmt7Y%3D (Pubitemid 37407169)
29. S. Nielsen A. Schmitz R.E. Knudsen J. Dollerup C.E. Mogensen 1994 Enalapril versus bendroflumethiazide in type 2 diabetes complicated by hypertension Q J Med 87 747 754 1:STN:280:DyaK2M7mt1Kqsw%3D%3D
30. OfficersCoordinators for the ALLHAT Collaborative Research Group. 2002 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA. 288 2981 2997 10.1001/jama.288.23.2981 (Pubitemid 35471160)
31. P. Verdecchia F. Angeli G.P. Reboldi R. Gattobigio 2005 New-onset diabetes in treated hypertensive patients Curr Hypertens Rep 7 174 179 15913490 10.1007/s11906-005-0006-3 1:CAS:528:DC%2BD2MXhtFSkt7nM
32. A.J. Zillich J. Garg S. Basu G.L. Bakris B.L. Carter 2006 Thiazide diuretics, potassium, and the development of diabetes: a quantitative review Hypertension 48 219 224 16801488 10.1161/01.HYP.0000231552.10054.aa 1:CAS:528:DC%2BD28XmvFalu74%3D (Pubitemid 44309815)
33. G. Bakris M. Molitch A. Hewkin 2006 Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome Diabetes Care 29 2592 2597 17130190 10.2337/dc06-1373 1:CAS:528:DC%2BD2sXhtVGhsQ%3D%3D (Pubitemid 44912184)
34. R. Cooper-Dehoff J.D. Cohen G.L. Bakris 2006 Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]) Am J Cardiol 98 890 894 16996868 10.1016/j.amjcard.2006.04.030 1:CAS:528:DC%2BD28XpvFemsLY%3D (Pubitemid 44402257)
35. C.J. Pepine E.M. Handberg R.M. Cooper-DeHoff 2003 A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial JAMA 290 2805 2816 14657064 10.1001/jama.290.21.2805 1:CAS:528:DC%2BD3sXps1Crurk%3D (Pubitemid 37509488)